Relmada Therapeutics
RLMD
134 hedge funds and large institutions have $954M invested in Relmada Therapeutics in 2022 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 13 closing their positions.
250% more funds holding in top 10
Funds holding in top 10: 2 → 7 (+5)
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
104% more capital invested
Capital invested by funds: $468M → $954M (+$485M)
39% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 33
19% more funds holding
Funds holding: 113 → 134 (+21)
3.48% more ownership
Funds ownership: 82.3% → 85.77% (+3.5%)
41% less call options, than puts
Call options by funds: $117M | Put options by funds: $198M
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$62.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11.6M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$6.74M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$4.85M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.17M |
Top Sellers
| 1 |
CAC
Cowen and Company
New York
|
-$23.6M |
| 2 |
VA
VR Adviser
New York
|
-$20.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.1M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.58M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.26M |
RLMD Hedge Fund Activity: Q3 2022 in Review
134 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2022, worth a combined $954M — up 104% from $468M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RLMD positions and 13 closed out — a net gain of 21 holders — while 46 added to existing stakes and 33 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $62.7M. The largest seller was Cowen and Company, cutting an estimated $23.6M.
- 134 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2022, up from 113 in Q2 2022.
- Funds reported $954M of Relmada Therapeutics stock for Q3 2022, up 104% quarter-over-quarter.
- 34 funds opened new Relmada Therapeutics positions in Q3 2022 and 13 closed out, a net change of +21 holders.
- The largest Relmada Therapeutics buyer in Q3 2022 was Perceptive Advisors, an estimated $62.7M added.
- The largest Relmada Therapeutics seller in Q3 2022 was Cowen and Company, an estimated $23.6M sold.
Based on aggregated 13F filings for Q3 2022.